{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:57:01Z","timestamp":1790269021857,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Travel Medicine and Infectious Disease"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.tmaid.2020.101658","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T19:34:01Z","timestamp":1585856041000},"page":"101658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Repurposing antimalarials and other drugs for COVID-19"],"prefix":"10.1016","volume":"34","author":[{"given":"Patricia","family":"Schlagenhauf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Grobusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gautret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.tmaid.2020.101658_bib1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1056\/NEJMc2001468","article-title":"Transmission of 2019-nCoV infection from an asymptomatic contact in Germany","volume":"382","author":"Rothe","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmaid.2020.101658_bib2","doi-asserted-by":"crossref","first-page":"m1066","DOI":"10.1136\/bmj.m1066","article-title":"COVID-19 and community mitigation strategies in a pandemic","volume":"368","author":"Ebrahim","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.tmaid.2020.101658_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101658_bib4","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID\u201019: results of an open\u2010label non\u2010randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.tmaid.2020.101658_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"7423","key":"10.1016\/j.tmaid.2020.101658_bib6","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/bmj.327.7423.1078","article-title":"Tolerability of malaria chemoprophylaxis in non-immune travellers to Sub-Saharan Africa: a multi-centre, randomised, double-blind, four-arm study","volume":"327","author":"Schlagenhauf","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.tmaid.2020.101658_bib7","unstructured":"WHO SOLIDARITY."},{"key":"10.1016\/j.tmaid.2020.101658_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tmaid.2019.06.012","article-title":"Systematic review of the therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS \u2013CoV)","volume":"30","author":"Momattin","year":"2019","journal-title":"Trav Med Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101658_bib9","doi-asserted-by":"crossref","first-page":"101615","DOI":"10.1016\/j.tmaid.2020.101615","article-title":"Remdesivir as a possible therapeutic option for the COVID_19","author":"Al-Tawfiq","year":"2020","journal-title":"Trav Med Infect Dis"},{"issue":"3","key":"10.1016\/j.tmaid.2020.101658_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.tmaid.2020.101658_bib11","series-title":"Teicoplanin potently blocks the cell entry of 2019-nCoV","first-page":"935387","author":"Zhang","year":"20200205"},{"key":"10.1016\/j.tmaid.2020.101658_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"}],"container-title":["Travel Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893920301265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893920301265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:04:23Z","timestamp":1761487463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477893920301265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":12,"alternative-id":["S1477893920301265"],"URL":"https:\/\/doi.org\/10.1016\/j.tmaid.2020.101658","relation":{},"ISSN":["1477-8939"],"issn-type":[{"value":"1477-8939","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing antimalarials and other drugs for COVID-19","name":"articletitle","label":"Article Title"},{"value":"Travel Medicine and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmaid.2020.101658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101658"}}